GlaxoSmithKline

Glaxo leukemia drug gets FDA approval NEW YORK - GlaxoSmithKline PLC received FDA approval for its drug Arzerra as a treatment for chronic lymphocytic leukemia, a slowly progressing cancer of the blood and bone marrow. The FDA said in a...

In this article: FDA, Leukemia, Glaxo, Progressive multifocal leukoencephalopathy, NEW YORK, and Philadelphia

Glaxo signs record $2.1 bln deal for Genmab drug LONDON (Reuters) - GlaxoSmithKline Plc <GSK.L> has bought global rights to Danish biotech company Genmab's <GEN.CO> most promising new drug, a treatment for leukemia, in a record deal worth up...

In this article: Genmab, Glaxo, Cancer, ImClone Systems Inc., Arranon, Leukemia, Erbitux, Arthritis, MabThera, and Rheumatoid arthritis

...market Arzerra to treat leukemia in patients that have failed to respond to other therapies after it received U.S. regulatory approval late Monday. GlaxoSmithKline and Denmark's Genmab, up 4.2%, developed the drug that was approved under...

In this article: Akzo Nobel, Europe, Leukemia, Renault, Fiat, U.S., Revenue, and Peugeot

...documents released on Wednesday said. Shares of Danish biotech company Genmab fell 17.5 percent in Copenhagen, while shares of much larger Glaxo gained 0.9 percent on the New York Stock Exchange. Food and Drug Administration staff said...

In this article: Food and Drug Administration, Genmab, Glaxo, Leukemia, Alemtuzumab, and Fludarabine

The agreement for the HuMax-CD20 antibody includes an initial license fee of 582 million kroner ($102 million), Glaxo buying a stake of just over 10 percent in Genmab and milestone payments totaling 9 billion kroner ($1.6 billion).

In this article: Glaxo, Genmab A/S, Seretide, Avandia, Leukemia, Cervical cancer, Asthma, Rheumatoid arthritis, and Hodgkin's lymphoma

UPDATE 1-Glaxo, Genmab say drug effective against leukemia An early look at data from a pivotal trial of the experimental drug Arzerra showed it curbed cancer in adults with a common form of leukemia, GlaxoSmithKline Plc <GSK.L> and Genmab...

In this article: Leukemia, Genmab A/S, Cancer, American Society of Hematology, and Ofatumumab

...in 1999. The company announced that this novel immune stimulant may have significant medical use for the treatment and prevention of infectious diseases, and may also contribute to the treatment of immune deficiency disorders. They added...

In this article: Belimumab, Antibody, Rheumatoid arthritis, Baff-r, Systemic lupus erythematosus, Calcium, Leukemia, Bcl-2, and Multiple myeloma

...breast cancer, leukemia and prostate cancer. The following investigational presentations reflect the broad spectrum of GSK-sponsored studies being presented at this year's ASCO Congress: Kidney Cancer: New, pivotal Phase III data...

In this article: Cancer, Lapatinib, HER2, Breast cancer, Renal cell carcinoma, Taxane, Surgery, Fludarabine, and Capecitabine

...for ofatumumab to treat chronic lymphocitic leukemia. We will continue to expand the development for this product working with our partner, GSK, and sharing development costs. We also expect to advance other clinical and pre-clinical...

In this article: Genmab, Revenue, Ofatumumab, Trademark, US Food And Drug Administration, US, Balance sheet, and European Medicines Agency